实施干预措施减少哮喘患者过度依赖短效β2受体激动剂的可行性与影响:专家意见
哮喘仍是全球重大健康问题,管理实践常低于当前推荐。SABINA项目显示短效β2受体激动剂过度依赖显著加重疾病负担。20名国际医疗从业者召开峰会,讨论五项减少短效β2受体激动剂过度依赖的创新干预措施(英国SENTINEL质量改进项目、台湾按绩效付费项目、西班牙哮喘正确护理项目、阿根廷无短效β2受体激动剂哮喘门诊、阿联酋改良急诊出院流程与短效β2受体激动剂警报系统),并评估其跨国实施可行性。基于证据回顾,专家提出六大主题以应对过度依赖,包括在医疗系统内一致提供服务、针对医疗从业者和患者的教育举措、采用无短效β2受体激动剂治疗范式(提供抗炎治疗联合速效支气管扩张剂缓解症状)、监管非处方短效β2受体激动剂购买、让政策制定者参与将循证治疗推荐整合入常规临床实践、扩大数字技术使用。减少短效β2受体激动剂过度依赖需要临床医生、药师和政策制定者协调努力。
要点
- SABINA项目显示短效β2受体激动剂过度依赖显著加重哮喘疾病负担,是当前管理实践与推荐之间的重要差距。
- 五项创新干预措施包括英国SENTINEL质量改进项目、台湾按绩效付费项目、西班牙哮喘正确护理项目、阿根廷无短效β2受体激动剂哮喘门诊、阿联酋改良急诊出院流程与短效β2受体激动剂警报系统。
- 专家提出采用无短效β2受体激动剂治疗范式,即提供抗炎治疗联合速效支气管扩张剂缓解症状。
- 专家建议监管非处方短效β2受体激动剂购买,并针对医疗从业者和患者开展教育举措以减少过度依赖驱动因素。
- 减少短效β2受体激动剂过度依赖需要临床医生、药师和政策制定者协调努力,制定并调整策略以提高对短效β2受体激动剂过度使用临床和经济负担的认识。
适用人群与场景
- 哮喘患者,尤其是存在短效β2受体激动剂过度依赖者。
- 涉及急诊科出院流程中的哮喘患者管理。
处置流程与药物剂量
- 采用无短效β2受体激动剂治疗范式:提供抗炎治疗联合速效支气管扩张剂用于症状缓解。
- 监管非处方短效β2受体激动剂购买。
- 开展针对医疗从业者和患者的教育举措以减少短效β2受体激动剂过度依赖的驱动因素。
研究设计与关键结果
- 20名国际医疗从业者受邀参加峰会,讨论五项减少短效β2受体激动剂过度依赖的创新干预措施并评估跨国实施可行性。
- 五项干预措施包括:英国SENTINEL质量改进项目、台湾按绩效付费项目、西班牙哮喘正确护理项目、阿根廷无短效β2受体激动剂哮喘门诊、阿联酋改良急诊出院流程与短效β2受体激动剂警报系统。
- 专家基于证据回顾提出六大主题以应对短效β2受体激动剂过度依赖。
证据类型、等级与局限
- 证据类型:专家意见。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,减少短效β2受体激动剂过度依赖需要临床医生、药师和政策制定者协调努力,制定并调整策略以提高对短效β2受体激动剂过度使用临床和经济负担的认识,并解决将循证推荐整合入常规临床实践的地方/国家障碍。
- 作者提出六大主题:在各国医疗系统内一致提供服务以促进最佳治疗方法和资源分配的标准化;针对医疗从业者和患者的教育举措以减轻短效β2受体激动剂过度依赖的驱动因素;采用无短效β2受体激动剂治疗范式;监管非处方短效β2受体激动剂购买;让政策制定者参与将当前循证治疗推荐整合入常规临床实践;扩大数字技术使用作为以患者为中心方法和监测处方实践的关键组成部分。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Asthma poses a significant global health problem. Despite the availability of effective treatments, management practices often fall short of current recommendations. The SABA use IN Asthma (SABINA) programme demonstrated that short-acting β2-agonist (SABA) over-reliance significantly contributes to disease burden. A panel of 20 international healthcare practitioners (HCPs) invited to a summit meeting discussed five innovative interventions to reduce SABA over-reliance and assessed the feasibility of implementing them across countries. The interventions included the SABA rEductioN Through ImplemeNting Hull asthma guidELines (SENTINEL) quality improvement programme in the UK, the pay-for-performance (P4P) programme in Taiwan, the Asthma Right Care (ARC) programme in Spain, a SABA-free asthma clinic in Argentina, and a modified emergency department discharge protocol and SABA alert system in the United Arab Emirates. Following a review of the available clinical evidence from these five interventions, the HCPs proposed six themes to tackle SABA over-reliance: (1) consistent delivery of services across healthcare systems in individual countries to facilitate standardisation of optimal treatment approaches and resource allocation; (2) educational initiatives targeted at HCPs and patients to mitigate drivers of SABA over-reliance; (3) adopting a SABA-free treatment paradigm that provides concomitant anti-inflammatory therapy with a fast-acting bronchodilator for symptom relief; (4) regulating over-the-counter SABA purchase without a prescription; (5) engaging policymakers to integrate current evidence-based treatment recommendations into routine clinical practice; and (6) expanding use of digital technology as a key component of a patient-centric approach and monitoring prescribing practices. Since SABAs were the preferred reliever for > 30 years, reducing SABA over-reliance will necessitate a considerable shift in asthma management practices. This transition requires coordinated efforts among clinicians, pharmacists, and policymakers to develop and tailor strategies for raising awareness of the clinical and economic burden of SABA overuse and address local/national barriers to integration of evidence-based recommendations in routine clinical practice.
参考来源
- Nannini L, Aisanov Z, Aksu K, et al. The Feasibility and Impact of Implementing Interventions to Reduce Short-Acting β2-Agonist Over-Reliance in Asthma: An Expert Opinion. Adv Ther. 2025. PMID: 40768188. doi:10.1007/s12325-025-03293-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。